| Literature DB >> 26247937 |
You-Lin Tain1,2, Chien-Ning Hsu3,4, Julie Y H Chan5, Li-Tung Huang6,7.
Abstract
Maternal nutrition can affect development, leading to long-term effects on the health of offspring. The most common outcome is programmed hypertension. We examined whether alterations in renal transcriptome are responsible for generating programmed hypertension among four different models using next-generation RNA sequencing (NGS) technology. Pregnant Sprague-Dawley rats received 50% caloric restriction (CR), intraperitoneal injection of 45 mg/kg streptozotocin, 60% high-fructose (HF) diet, or 1% NaCl in drinking water to conduct CR, diabetes, HF, or high-salt models, respectively. All four models induced programmed hypertension in adult male offspring. We observed 16 shared genes in a two-week-old kidney among four different models. The identified differential expressed genes (DEGs) that are related to the regulation of blood pressure included Adrb3, Alb, Apoe, Calca, Kng1, Adm2, Guca2b, Hba2, Hba-a2, and Ppara. The peroxisome proliferator-activated receptor (PPAR) signaling pathway and glutathione metabolism pathway were shared by the CR, diabetes, and HF models. Conclusively, a variety of maternal nutritional insults induced the same phenotype-programmed hypertension with differential alterations of renal transcriptome in adult male offspring. The roles of DEGs identified by the NGS in this study deserve further clarification to develop ideal maternal dietary interventions and thus spare the next generations from the burden of hypertension.Entities:
Keywords: developmental programming; diabetes; fructose; hypertension; next generation sequencing; nutrition
Mesh:
Substances:
Year: 2015 PMID: 26247937 PMCID: PMC4581224 DOI: 10.3390/ijms160817826
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Effects of maternal caloric restriction (CR), streptozotocin-induced diabetes, high fructose (HF) intake, and high salt (HS) intake on systolic blood pressure in male adult offspring at 12 weeks of age. n = 6–10 per group. * p < 0.05 vs. respective control.
Figure 2Venn diagram depicting unique and shared (overlapping circles) sets of differentially expressed genes (DEGs) in the kidney between CR, streptozotocin-induced diabetes, HF, and HS groups at two weeks of age. A total of 16 combined DEGs are listed in the right panel.
Significantly regulated Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in the two-week-old offspring kidneys of maternal CR, diabetes, HF, and HS.
| Term | Count | % | Benjamini | ||
|---|---|---|---|---|---|
| CR | |||||
| Ribosome | 22 | 3.0 | 1.1 × 10−14 | 1.4 × 10−12 | |
| Cell cycle | 16 | 2.2 | 3.6 × 10−6 | 2.4 × 10−4 | |
| Oocyte meiosis | 9 | 1.2 | 1.6 × 10−2 | 5.3 × 10−1 | |
| DNA replication | 5 | 0.7 | 1.9 × 10−2 | 4.8 × 10−1 | |
| Fatty acid metabolism | 5 | 0.7 | 3.4 × 10−2 | 6.1 × 10−1 | |
| Tryptophan metabolism | 5 | 0.7 | 3.7 × 10−2 | 5.7 × 10−1 | |
| Homologous recombination | 4 | 0.5 | 4.0 × 10−2 | 5.5 × 10−1 | |
| Progesterone-mediated oocyte maturation | 7 | 0.9 | 4.3 × 10−2 | 5.2 × 10−1 | |
| Valine, leucine, and isoleucine degradation | 5 | 0.7 | 4.6 × 10−2 | 5.1 × 10−1 | |
| Prostate cancer | 7 | 0.9 | 4.9 × 10−2 | 5.0 × 10−1 | |
| PPAR signaling pathway | 6 | 0.8 | 5.8 × 10−2 | 5.2 × 10−1 | |
| Glutathione metabolism | 5 | 0.7 | 5.9 × 10−2 | 5.0 × 10−1 | |
| Arginine and proline metabolism | 5 | 0.7 | 7.0 × 10−2 | 5.3 × 10−1 | |
| Diabetes | |||||
| Ribosome | 14 | 1.6 | 2.6 × 10−6 | 3.8 × 10−4 | |
| ABC transporters | 7 | 0.8 | 3.0 × 10−3 | 2.0 × 10−1 | |
| Complement and coagulation cascades | 8 | 0.9 | 8.0 × 10−3 | 3.3 × 10−1 | |
| Spliceosome | 10 | 1.1 | 1.8 × 10−2 | 4.9 × 10−1 | |
| Antigen processing and presentation | 8 | 0.9 | 2.6 × 10−2 | 5.4 × 10−1 | |
| Prostate cancer | 8 | 0.9 | 2.9 × 10−2 | 5.1 × 10−1 | |
| Drug metabolism | 7 | 0.8 | 3.1 × 10−2 | 4.9 × 10−1 | |
| Histidine metabolism | 4 | 0.4 | 4.3 × 10−2 | 5.6 × 10−1 | |
| Metabolism of xenobiotics by cytochrome P450 | 6 | 0.7 | 4.7 × 10−2 | 5.5 × 10−1 | |
| ECM-receptor interaction | 7 | 0.8 | 5.1 × 10−2 | 5.4 × 10−1 | |
| Tryptophan metabolism | 5 | 0.6 | 5.3 × 10−2 | 5.1 × 10−1 | |
| Glutathione metabolism | 5 | 0.6 | 8.2 × 10−2 | 6.5 × 10−1 | |
| PPAR signaling pathway | 6 | 0.7 | 8.5 × 10−2 | 6.3 × 10−1 | |
| HF | |||||
| PPAR signaling pathway | 9 | 2.7 | 9.2 × 10−6 | 8.7 × 10−4 | |
| Butanoate metabolism | 4 | 1.2 | 1.3 × 10−2 | 4.6 × 10−1 | |
| Arachidonic acid metabolism | 5 | 1.5 | 2.1 × 10−2 | 4.8 × 10−1 | |
| Fatty acid metabolism | 4 | 1.2 | 2.5 × 10−2 | 4.5 × 10−1 | |
| Glutathione metabolism | 4 | 1.2 | 3.9 × 10−2 | 5.3 × 10−1 | |
| Metabolism of xenobiotics by cytochrome P450 | 4 | 1.2 | 6.1 × 10−2 | 6.3 × 10−1 | |
| Tyrosine metabolism | 3 | 0.9 | 9.2 × 10−2 | 7.3 × 10−1 | |
| Drug metabolism | 4 | 1.2 | 9.3 × 10−2 | 6.9 × 10−1 | |
| HS | |||||
| Cell adhesion molecules (CAMs) | 8 | 3.3 | 3.0 × 10−4 | 2.3 × 10−2 | |
| Complement and coagulation cascades | 4 | 1.6 | 2.4 × 10−2 | 6.1 × 10−1 | |
| Hematopoietic cell lineage | 4 | 1.6 | 3.2 × 10−2 | 5.6 × 10−1 | |
| Systemic lupus erythematosus | 4 | 1.6 | 4.6 × 10−2 | 5.9 × 10−1 | |
| Intestinal immune network for IgA production | 3 | 1.2 | 6.1 × 10−2 | 6.1 × 10−1 | |
| Graft- | 3 | 1.2 | 7.6 × 10−2 | 6.3 × 10−1 | |
| Allograft rejection | 3 | 1.2 | 8.1 × 10−2 | 6.0 × 10−1 | |
Fold changes in genes involved in kidney development in the kidneys of offspring at two weeks of age exposed to maternal CR, diabetes, HF, and HS.
| Gene ID | Gene Symbol | CR | Diabetes | HF | HS | |||
|---|---|---|---|---|---|---|---|---|
| Expansion and survival of renal stem cells | ||||||||
| ENSRNOG00000009425 | 0.61 | 0.57 | 1.31 | 1.34 | ||||
| ENSRNOG00000012278 | 0.52 | 0.55 | 0.87 | |||||
| ENSRNOG00000016050 | 1.08 | 1.33 | 0.87 | 1.03 | ||||
| ENSRNOG00000016374 | 0.72 | 1.28 | 0.89 | 0.99 | ||||
| ENSRNOG00000009972 | 0.95 | 1.38 | 1.04 | 1.28 | ||||
| Formation and extension of the primary nephric duct | ||||||||
| ENSRNOG00000013074 | 1.16 | 1.51 | 0.98 | 1.13 | ||||
| ENSRNOG00000014751 | 3.3 | 1.06 | 1.56 | 1.75 | ||||
| ENSRNOG00000012819 | ||||||||
| ENSRNOG00000017438 | 1.18 | 1.28 | 1.64 | 1.38 | ||||
| ENSRNOG00000003840 | 1.05 | 1.17 | 0.75 | 0.86 | ||||
| ENSRNOG00000029598 | 0.99 | 1.45 | 0.85 | 0.79 | ||||
| ENSRNOG00000009694 | 0.81 | 0.93 | 0.88 | 1.01 | ||||
| ENSRNOG00000025371 | 1.14 | 0.77 | 0.85 | 1.32 | ||||
| ENSRNOG00000010058 | 1.4 | 1.26 | 1.02 | 1.17 | ||||
| ENSRNOG00000008430 | ND | 1.04 | 278 | |||||
| ENSRNOG00000013851 | 1.23 | 0.86 | 1.21 | 1.41 | ||||
| ENSRNOG00000022777 | 1.58 | 1.55 | ||||||
| ENSRNOG00000007590 | 0.62 | 0.79 | 1.3 | 1.28 | ||||
| ENSRNOG00000019336 | 0.37 | 0.58 | 0.71 | 0.76 | ||||
| ENSRNOG00000026053 | 0.57 | 1.21 | 0.83 | |||||
| Glomerular development | ||||||||
| ENSRNOG00000019598 | 0.87 | 0.88 | 1.22 | 1.24 | ||||
| ENSRNOG00000016700 | 1.14 | 1.1 | 0.81 | 0.91 | ||||
| ENSRNOG00000001312 | 1.15 | 1.5 | 1 | 1.09 | ||||
| ENSRNOG00000017197 | 0.93 | 1.28 | 0.9 | 1.24 | ||||
| ENSRNOG00000011987 | 0.69 | 0.67 | 0.95 | 0.8 | ||||
| ENSRNOG00000014917 | 0.81 | 0.61 | 0.98 | 0.83 | ||||
| ENSRNOG00000017155 | 1.13 | 1.31 | 1.1 | 1.29 | ||||
| ENSRNOG00000016408 | 1.18 | 1.67 | 0.82 | 1.18 | ||||
| ENSRNOG00000016281 | 0.94 | 1.38 | 0.88 | 0.99 | ||||
| ENSRNOG00000023972 | 1.09 | 1.75 | 0.77 | 0.91 | ||||
| ENSRNOG00000014851 | 1.14 | 1.07 | 0.8 | 1 | ||||
| ENSRNOG00000018951 | 1.36 | 1.52 | 0.85 | 0.96 | ||||
| Initiation of metanephric development | ||||||||
| ENSRNOG00000020417 | 0.93 | 0.9 | 1.08 | 1.22 | ||||
| ENSRNOG00000002833 | 0.73 | 1.09 | 1 | 1.07 | ||||
| ENSRNOG00000013166 | 1.1 | 1.9 | 0.7 | 1.12 | ||||
| ENSRNOG00000003807 | 0.75 | 1.27 | 0.85 | |||||
| ENSRNOG00000015982 | 1.18 | 1.29 | 1.3 | |||||
| ENSRNOG00000007002 | 0.64 | 0.95 | 1.12 | |||||
| ENSRNOG00000017392 | 1.54 | 0.82 | ||||||
| ENSRNOG00000020652 | 0.73 | 0.81 | 0.88 | 1.14 | ||||
| ENSRNOG00000003866 | 1.12 | 1.06 | 0.95 | 0.72 | ||||
| ENSRNOG00000020792 | 0.94 | 1.7 | 1.53 | |||||
| ENSRNOG00000001785 | 0.98 | 1.46 | 1.05 | 1.23 | ||||
| ENSRNOG00000016848 | 1.08 | 1.05 | 0.93 | 0.94 | ||||
| ENSRNOG00000038571 | 0.87 | 1.08 | 0.79 | 0.93 | ||||
| Mesoderm patterning | ||||||||
| ENSRNOG00000004210 | 0.61 | 0.57 | ||||||
| ENSRNOG00000014253 | 0.7 | 1.02 | 0.89 | 1.24 | ||||
| ENSRNOG00000026203 | 0.75 | 1.04 | 0.91 | 1.16 | ||||
| ENSRNOG00000002812 | 0.99 | 1.35 | 0.99 | 1 | ||||
| ENSRNOG00000021276 | 1.72 | 0.86 | 1.05 | |||||
| ENSRNOG00000000109 | ND | ND | ND | ND | ||||
| ENSRNOG00000006530 | 0.97 | 1.32 | 0.96 | 0.98 | ||||
| ENSRNOG00000000556 | ND | ND | ND | |||||
| ENSRNOG00000017800 | 1.45 | 1.49 | 1.01 | 1.21 | ||||
| ENSRNOG00000009482 | 0.77 | 0.77 | 1 | 1.01 | ||||
| Nephron development | ||||||||
| ENSRNOG00000004517 | 0.55 | 0.77 | 0.64 | |||||
| ENSRNOG00000019322 | 0.81 | 1.14 | 0.89 | 1.04 | ||||
| ENSRNOG00000018835 | 1.17 | 1.58 | 0.74 | 0.98 | ||||
| ENSRNOG00000004346 | 1.18 | 0.83 | 1.06 | |||||
| ENSRNOG00000000442 | 1.32 | 1.11 | 0.9 | 1.07 | ||||
| ENSRNOG00000020155 | 0.87 | 0.91 | 0.85 | 0.8 | ||||
| ENSRNOG00000002079 | 0.51 | 0.53 | 0.79 | 0.91 | ||||
| ENSRNOG00000013535 | 0.66 | 0.87 | 0.77 | 0.83 | ||||
| ENSRNOG00000013481 | 0.9 | 1.38 | 0.74 | 0.85 | ||||
ND = not detectable; Significant results are highlighted in bold.